Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis
Status:
Completed
Trial end date:
2004-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to confirm and extend the data from previous studies and to
demonstrate the efficacy (in terms of signs and symptoms) and safety of monotherapy with
CDP870 administered SC every 4 weeks compared to placebo in patients with active RA who had
failed at least one DMARD.